Big Moves in AI-Driven Oncology: Pathos Secures Major Backing

May 15, 2025 · Pathos AI

Pathos AI Raises $365 Million in Series D Financing

The financing brings the oncology-focused AI drug developer's post-money valuation to approximately $1.6 billion.

Pathos AI announced a $365 million Series D to advance its clinical-stage oncology pipeline and to continue building its AI foundation model for oncology. The company says the model draws on clinical, molecular, and imaging data to support asset selection, trial design, and biomarker discovery. Iker Huerga, CEO, said the funding will help accelerate development and bring the right therapies to patients faster.

Read the full announcement

Source: Pathos AI, via GlobeNewswire. Statements about the company's technology are the company's own.